CL2019002362A1 - Formulaciones de evolocumab de baja viscosidad y alta concentración y métodos de elaboración de las mismas. - Google Patents

Formulaciones de evolocumab de baja viscosidad y alta concentración y métodos de elaboración de las mismas.

Info

Publication number
CL2019002362A1
CL2019002362A1 CL2019002362A CL2019002362A CL2019002362A1 CL 2019002362 A1 CL2019002362 A1 CL 2019002362A1 CL 2019002362 A CL2019002362 A CL 2019002362A CL 2019002362 A CL2019002362 A CL 2019002362A CL 2019002362 A1 CL2019002362 A1 CL 2019002362A1
Authority
CL
Chile
Prior art keywords
formulations
methods
making
high concentration
low viscosity
Prior art date
Application number
CL2019002362A
Other languages
English (en)
Inventor
Christopher James Sloey
Sekhar Kanapuram
Huanchun Cui
Chio Mui Chan
Elaheh Binabaji
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2019002362A1 publication Critical patent/CL2019002362A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROPORCIONAN EN EL PRESENTE DOCUMENTO FORMULACIONES DE POLIPÉPTIDOS DE UNIÓN A PCSK9, TALES COMO LAS QUE COMPRENDEN EVOLOCUMAB, QUE COMPRENDEN N-ACETIL ARGININA Y TIENEN VISCOSIDADES REDUCIDAS EN COMPARACIÓN CON FORMULACIONES QUE CARECEN DE N-ACETIL ARGININA. TAMBIÉN SE PROPORCIONAN EN EL PRESENTE DOCUMENTO MÉTODOS PARA FORMULAR DICHAS COMPOSICIONES QUE SON VENTAJOSAS EN CUANTO CONSERVAN DETERMINADOS COMPONENTES. DICHAS FORMULACIONES QUE COMPRENDEN POLIPÉPTIDOS DE UNIÓN A PCSK9 SE PUEDEN ADMINISTRAR A PACIENTES PARA TRATAR Y/O PREVENIR ENFERMEDADES, AFECCIONES Y TRASTORNOS RELACIONADOS CON PCSK9.
CL2019002362A 2017-02-22 2019-08-21 Formulaciones de evolocumab de baja viscosidad y alta concentración y métodos de elaboración de las mismas. CL2019002362A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762462266P 2017-02-22 2017-02-22

Publications (1)

Publication Number Publication Date
CL2019002362A1 true CL2019002362A1 (es) 2019-11-29

Family

ID=61617101

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002362A CL2019002362A1 (es) 2017-02-22 2019-08-21 Formulaciones de evolocumab de baja viscosidad y alta concentración y métodos de elaboración de las mismas.

Country Status (17)

Country Link
US (2) US11464857B2 (es)
EP (1) EP3585821A1 (es)
JP (1) JP7377596B2 (es)
KR (2) KR20190120257A (es)
CN (1) CN110536906A (es)
AR (2) AR110938A1 (es)
AU (1) AU2018224095A1 (es)
BR (1) BR112019017393A8 (es)
CA (1) CA3053394A1 (es)
CL (1) CL2019002362A1 (es)
EA (1) EA201991951A1 (es)
IL (1) IL268515A (es)
MA (1) MA47601A (es)
MX (1) MX2019009952A (es)
SG (1) SG11201907505TA (es)
UY (1) UY37611A (es)
WO (1) WO2018156741A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038462B1 (ru) 2014-10-23 2021-08-31 Эмджен Инк. Снижение вязкости фармацевтических составов
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
AU2020263318A1 (en) * 2019-04-23 2021-10-21 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
WO2022217021A1 (en) * 2021-04-09 2022-10-13 Avantor Performance Materials, Llc Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
JP4129178B2 (ja) 2000-11-07 2008-08-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 安定化されたインターフェロン組成物
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2006516636A (ja) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
PL2335725T3 (pl) 2003-04-04 2017-04-28 Genentech, Inc. Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
BR112012011539A8 (pt) 2009-11-17 2017-12-26 Ipsen Pharma Sas formulação para a combinação de hgh e rhigf-1
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
JP2015519382A (ja) 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
EA038462B1 (ru) 2014-10-23 2021-08-31 Эмджен Инк. Снижение вязкости фармацевтических составов
AU2015357068B2 (en) 2014-12-03 2021-07-29 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
IL307684A (en) * 2016-09-29 2023-12-01 Amgen Inc Low viscosity antigen binding proteins and methods for their preparation
WO2018067987A1 (en) * 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
KR20240060732A (ko) 2024-05-08
US20180237501A1 (en) 2018-08-23
AU2018224095A1 (en) 2019-08-22
US11464857B2 (en) 2022-10-11
SG11201907505TA (en) 2019-09-27
MA47601A (fr) 2020-01-01
BR112019017393A8 (pt) 2022-03-03
EA201991951A1 (ru) 2020-01-21
WO2018156741A1 (en) 2018-08-30
CN110536906A (zh) 2019-12-03
EP3585821A1 (en) 2020-01-01
BR112019017393A2 (pt) 2020-04-14
JP2018154616A (ja) 2018-10-04
JP7377596B2 (ja) 2023-11-10
MX2019009952A (es) 2019-10-14
CA3053394A1 (en) 2018-08-30
TW201841650A (zh) 2018-12-01
AR110938A1 (es) 2019-05-15
US20230226177A1 (en) 2023-07-20
IL268515A (en) 2019-09-26
KR20190120257A (ko) 2019-10-23
UY37611A (es) 2018-08-31
AR125766A2 (es) 2023-08-09

Similar Documents

Publication Publication Date Title
CL2019002362A1 (es) Formulaciones de evolocumab de baja viscosidad y alta concentración y métodos de elaboración de las mismas.
ECSP19043710A (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2018001404A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos.
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
BR112017011536A2 (pt) terapias de combinação
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112013016021A2 (pt) métodos e composições adequadas para gerenciar glicemia em animais
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
BR112017013696A2 (pt) peptídeos e seu uso no tratamento de pele
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112015020182A2 (pt) uso cosmético de queuina ou de um precursor ou um derivado dessa como ingrediente ativo, uso de queuina ou um precursor ou um derivado dessa como ingrediente ativo, composição cosmética e processo de tratamento cosmético para prevenir e/ou tratar sinais de envelhecimento da pele e/ou anexos cutâneos